SCHEMBL7161968

SCHEMBL7161968

CCCCCc1nc(-c2ccsc2)c[nH]1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.41
DRD2 P14416 1/20 0.40
HTR6 P50406 1/20 0.40
ADORA1 P30542 4/20 0.39
ADORA2A P29274 3/20 0.39
ADORA3 P0DMS8 2/20 0.37
ADORA2B P29275 2/20 0.37
GSK3B P49841 1/20 0.37
GPR84 Q9NQS5 5/20 0.35
KDM4A O75164 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
CASP1 P29466 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946753 0.78 GPR84 (0.44) ADORA1ADORA2AADORA3GSK3BGPR84
SCHEMBL11297462 0.78 GPR84 (0.44) ADORA1ADORA2AADORA3GSK3BGPR84
SCHEMBL8016347 0.77 TLR8 (0.47) GSK3BALDH1A1HPGDHSD17B10
SCHEMBL4814536 0.75 GPR84 (0.42) ADORA1ADORA2AADORA3GSK3BGPR84
SCHEMBL6618330 0.74 GSK3B (0.44) ADORA1ADORA2AADORA3GSK3BGPR84
Ammonia Solution, Strong SCHEMBL27564785 0.73 GSK3B (0.43) ADORA1ADORA2AADORA3GSK3BGPR84
SCHEMBL7100910 0.72 GSK3B (0.41) PDGFRBGSK3BTSHRNPSR1HSD17B10
SCHEMBL8012182 0.72 TLR8 (0.44) GSK3BALDH1A1HPGDTSHRMAPK1
SCHEMBL13277717 0.72 GSK3B (0.43) ADORA1ADORA2AADORA3ADORA2BGSK3B
SCHEMBL6965532 0.72 PDGFRB (0.48) PDGFRBDRD2HTR6ADORA1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed